Skip to main content


Birthday Gatherings Increase COVID-19 Risk

How risky are family gatherings, birthday parties and informal social gatherings? A cross-sectional analysis suggests that birthdays may be associated with increased rates of COVID-19 infection within households where there is a high COVID-19 prevalence in the population. 

Knee Replacement in Obese OA is Cost Effective

Debates over ideal candidates for total knee replacement (TKR) in osteoarthritis patients often excludes those who are obese, but a recent article in the Annals of Internal Medicine suggests that TKR is both effective and cost-effective in obese patients (BMI >40 kg/m2) with

Pain Persists in RA, Even Without Inflammation

MedPage Today

One-third of patients with rheumatoid arthritis had unacceptably high levels of pain 5 years after diagnosis, often despite low levels of inflammation, Swedish researchers found.

Better Outcomes with Modern T2T in Pregnancy

With the expansion of knowledge regarding the safety of newer agents in pregnancy comes the PreCARA study showing that when pregnancy is planned and patients with rheumatoid arthritis (RA) are treated with a modified treat-to-target (T2T) approach, superior outcomes can be anticipated.

Progression from Psoriasis to Psoriatic Arthritis

The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).

FINCH 1 Trial Filgotinib in Rheumatoid Arthritis

The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the Janus kinase-1 (JAK1) preferential inhibitor filgotinib was superior to a tumour necrosis factor-α inhibitor (adalimumab) in active rheumatoid arthritis (RA) on methotrexate (MTX).

Treatment of MIS-C COVID in Kids

The NEJM has published results of a real-world efficacty trial showing that COVID infected children with the multisystem inflammatory syndrome in children (MIS-C) respond better to initial IVIG plus glucocorticoids (than IVIG alone) which was associated with less subsequent cardiovascular complic

Tofacitinib Efficacy in COVID-19 Pneumonia

NEJM has published the results of an observational trial wherein tofacitinib given to patients hospitalized with Covid-19 pneumonia, was shown to significantly lower risk of death or respiratory failure.

Which patients with psoriasis are at risk to develop PsA?

The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.

RheumNow Podcast - Speak Up! (6.18.2021)

Dr. Jack Cush talks on education, engagement and the challenge of speaking up, if not first!

Do B-cell targeted therapies still have a place for the treatment of Sjogren’s?

B-cells play a major role in the pathogenesis of primary Sjogren’s syndrome (pSS) through antibody-dependent and antibody-independent functions, as well as evident by progression to B-cell malignancies/lymphoma. Hence, targeting B-cell is attractive. Despite efficacy of B-cell depleting therapy with rituximab in Phase II trials and case series, it failed to meet its primary endpoint when investigated in two Phase III trials. It is worth noting that the primary endpoint used in both trials was a subjective measure. Post-hoc analyses however showed greater improvement in objective measures such as salivary flow rate and salivary gland ultrasound score in RTX-treated group vs placebo. Therefore, do B-cell targeted therapies still have a place for the treatment of pSS?

Reader beware! Interpretation of effectiveness & safety of JAKi vs bDMARDs in real world data

Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021.